50592-31-9

Basic information

• Product Name: 4-BROMOFLUOROBENZENE-D4
• Synonyms: 4-BROMOFLUOROBENZENE-D4;1-BROMO-4-FLUORO-BENZENE-RING-D4;1-Bromo-4-fluorobenzene-d4;p-Bromofluorobenzene-d4
• CAS NO: 50592-31-9
• Molecular Formula: C₆H₄BrF
• Molecular Weight: 179.02
• Mol File: 50592-31-9.mol

Chemical Properties

• Melting Point: -16 °C(lit.)
• Boiling Point: 150 °C(lit.)
• Flash Point: 60 °C
• Appearance: /
• Density: 1.629 g/mL at 25 °C
• Storage Temp.: Refrigerator
• Solubility: Chloroform (Sparingly), Ethyl Acetate (Slightly)
• CAS DataBase Reference: 4-BROMOFLUOROBENZENE-D4(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMOFLUOROBENZENE-D4(50592-31-9)
• EPA Substance Registry System: 4-BROMOFLUOROBENZENE-D4(50592-31-9)

Safety Data

• Hazard Codes: Xn
• Statements: 20-36/37/38
• Safety Statements: 26
• Hazardous Substances Data: 50592-31-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-BROMOFLUOROBENZENE-D4 is used as a key intermediate for the synthesis of atypical antipsychotic agents. Its unique dihalogenated benzene structure makes it a valuable building block in the development of novel pharmaceutical compounds with potential applications in the treatment of various psychiatric disorders.
Used in Research and Development:
In the field of research and development, 4-BROMOFLUOROBENZENE-D4 serves as an essential tool for studying the structure-activity relationships of atypical antipsychotic drugs. Its isotope-labeled nature allows for the investigation of various biological processes and interactions at the molecular level, contributing to a deeper understanding of the mechanisms underlying the therapeutic effects of these drugs.
Used in Drug Synthesis and Design:
4-BROMOFLUOROBENZENE-D4 is employed as a versatile starting material in the synthesis of a wide range of pharmaceutical compounds. Its dihalogenated benzene structure can be further modified and functionalized to create diverse molecules with potential applications in various therapeutic areas, including but not limited to, central nervous system disorders, cardiovascular diseases, and oncology.

Upstream product

• 1423-10-5 fluorobenzene-d5 

Downstream Products

• 874483-38-2 (4-fluoro-[2,3,5,6-2H₄]phenyl)(pyridin-4-yl)methanol 
• 1335333-86-2 1-(2,3,5.6-tetradeutero-4-fluorophenyl)ethanone 
• 1092655-71-4 C₆⁽²⁾H₄BrFMg 

Relevant articles and documents

INHIBITORS OF APOL1 AND METHODS OF USING SAME

The disclosure provides at least one entity chosen from compounds of Formula (I) pharmaceutically acceptable salts thereof, solvates of any of the foregoing, and deuterated derivatives of any of the foregoing, compositions comprising the same, and methods of using the same, including use in treating APOL1 mediated kidney disease.

INHIBITORS OF APOL1 AND METHODS OF USING SAME

The disclosure provides at least one entity chosen from compounds of formula (I), solid state forms of the same, compositions comprising the same, and methods of using the same, including use in treating focal segmental glomerulosclerosis (FSGS) and/or non-diabetic kidney disease (NDKD).

Aryl trifluoroborates in Suzuki-Miyaura coupling: The roles of endogenous aryl boronic acid and fluoride

Undercover agents: The biaryl coupling of an aryltrifluoroborate with an aryl bromide involves in situ hydrolysis of the boron reagent. The hydrolysis products are key components in ensuring that the reaction proceeds with high efficiency and avoids the e

Convenient methods for the synthesis of d4, d2 and d6 isotopomers of 4-(4-fluorobenzyl)piperidine

Pure 4-(4-fluoro-[2,3,5,6-2H4]benzyl)piperidine was prepared via the Grignard reaction of 4-fluoro-[2,3,5,6-2H 4]bromobenzene and pyridine-4-aldehyde followed by consecutive deoxygenation and heteroatomic ring saturation in the presence of palladium on carbon catalyst. An improved method for the catalytic H/D exchange in benzylic positions of 4-(4-fluorobenzyl)piperidine and its d4 derivative has also been described. Copyright